|[November 13, 2012]
First-of-Its-Kind Cancer Research Report Paves Way for More Coordinated Global Cancer Science
DALLAS --(Business Wire)--
A first-of-its-kind analysis of the world's investments in cancer
research lays the groundwork for greater global collaboration and focus
for the billions of dollars invested each year in cancer research
worldwide, according to the chair of the committee that compiled the
This inaugural report from the International Cancer Research Partnership
(ICRP), released today, brings together detailed data about cancer
research funding from more than 50 leading cancer organizations. It
shows that between 2005 and 2008, the ICRP member organizations alone
funded more than 20,000 cancer research grants totaling $4.6 to $4.8
billion USD each year. Breast cancer research grew to almost $1 billion,
or 20.6 percent of all cancer research funding, as of 2008.
"This first report tells us conclusively how research dollars have been
spent and what the international research community ought to be focused
on going forward," said Stephanie Reffey, Ph.D., Director of Research
Evaluation for Susan G. Komen for the Cure® and chair of the ICRP
committee since 2011. "This is a huge step forward for investing
research dollars strategically to create the greatest impact for people
facing cancer," she said.
Reffey discusses the report in more detail on the Komen
"It has been a privilege to represent Susan G. Komen on this panel and
to see firsthand the power of this international collaboration," Reffey
said. "The partners' resolve to collaborate, share best practices in
research management, and strategically coordinate their research
investments allows all of us to maximize the impact of cancer research."
Komen is the largest nonprofit funder of breast cancer research, with
more than $750 million invested since 1982.
The new report is available at ICRP's website
and covers all forms of cancer and investments in key research areas:
biology, etiology (the causes of disease), prevention, early detection,
diagnosis and prognosis, treatment, cancer control and survivorship, and
scientific model systems. This report also launches an international
cancer research classification system called the Common Scientific
Outline (CSO), and a global database to track research investments and
set benchmarks for the future.
ICRP expects to release periodic updates to this report, which will
include data from additional partners in the Netherlands, Australia and
Japan. The ICRP also is actively seeking additional cancer funding
organizations to contribute their portfolio information for future
About the International Cancer Research
The International Cancer Research Partnership was formed in 2000 and is
an active network of senior representatives from organizations united in
a collaborative effort to promote coordinated progress in cancer
research. Currently, the ICRP consists of cancer research funding
organizations within the United States, Canada, Europe, Australia and
Japan who have agreed to apply a common language-the Common Scientific
Outline (CSO)-for discussing, comparing, and presenting their cancer
research portfolios. The CSO classification system provides the tools
needed to lay the groundwork for collective portfolio analyses and
coordinated strategic planning among the Partner organizations.
ICRP members represent some of the largest funders of cancer research in
the world. Members share award funding data in a common format to allow
comparisons across all organizations. Part of the dataset is made
available to the public (https://www.icrpartnership.org/database.cfm)
and contributing partners have full access in a password-protected site.
Partners also enjoy access to analytical tools, collaborative forum
areas for information exchange in addition to joint evaluation reports
For more information, visit https://www.icrpartnership.org/Publications.cfm.
About Susan G. Komen for the Cure®
Nancy G. Brinker promised her dying sister, Susan G. Komen, that she
would do everything in her power to end breast cancer. Today, Susan G.
Komen for the Cure works to end breast cancer in the U.S. and throughout
the world through ground-breaking research, community health outreach,
advocacy and programs in more than 30 countries. Komen is the largest
nonprofit funder of breast cancer research with more than $750 million
invested since Komen's founding in 1982. Visit komen.org.
Connect with us on Facebook
[ Back To Telecom Signaling's Homepage ]